Trillium Therapeutics Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trillium Therapeutics

TRIL 20.36

+2.0%

Nov 26 2:56 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (112)	12/11/2017 11:19:37 PM
From: scaram(o)uche	Read Replies (1) of 294

>> Though still good, aren't some other players in the DLBCL space also reporting solid data? << Yes, but that's the way Joe Trader is thinking. What WE are hoping for is the holy grail.... dysfunctional, tumor-resident antigen presenting cells suddenly turning into machines that a Dendrite would admire. It's not looking at DLBCL activity head to head with other agents, it's demonstrated anticancer activity for a new biological paradigm. Maybe. >> The CTCL data looks pretty interesting << Fascinating. >> They really do need a partner. << Too busy revising the thread's header.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next